• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Research and Markets: Global Infectious Disease Treatment Market 2014-2018: Key Vendors Are F. Hoffmann-La Roche, Gilead Sciences, GSK , J&J Merck & Pfizer

    Research and Markets: Global Infectious Disease Treatment Market 2014-2018: Key Vendors Are F. Hoffmann-La Roche, Gilead Sciences, GSK , J&J Merck & Pfizer

  2. Research and Markets: Global Acute Respiratory Distress Syndrome Therapeutics Pipeline Review, H2 2014 - 10 Companies & 24 Drug Profiles

    Research and Markets: Global Acute Respiratory Distress Syndrome Therapeutics Pipeline Review, H2 2014 - 10 Companies & 24 Drug Profiles

  3. Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles

    Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles

  4. Peters: Don’t Be Scared by Scotland

    The U.K. will remain a good hunting ground for dividend-paying stocks even if Scotland decides to become independent, says Morningstar's Josh Peters.

  5. Award-Winning Brussels Public Affairs Agency Cambre Associates Joins IPREX

    Award-Winning Brussels Public Affairs Agency Cambre Associates Joins IPREX

  6. ProNova SC360 Selected for New Proton Center in Biopolis Singapore

    ProNova SC360 Selected for New Proton Center in Biopolis Singapore

  7. Where Are the Opportunities in U.S. Health Care?

    As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.

  8. ADR Shares End Mixed; Luxottica Shares Active

    ADR Shares End Mixed; Luxottica Shares Active

  9. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application

    NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application

  10. Research and Markets: Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market

    Research and Markets: Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.